Skip to main content
Equibles
REPL logo

REPL · Replimune Group, Inc.

Track REPL — free

Use REPL with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about REPL

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$14.97 -0.22 (-1.45%) At close · Aug 14
Going-concern doubt — cleared Aug 14, 2026

The latest filing states the doubt was alleviated.

“As described in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, substantial doubt existed about the Company's ability to continue as a going concern. The conditions that raised substantial doubt have been subsequently alleviated, as the Company raised approximately $141.0 million in net proceeds from an equity offering in August 2026.”
View the 10-Q filed Aug 14, 2026
Market Cap
$1.41B
Shares
94.22M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$14.97 Open$15.19 Day$14.69–15.39 52W close$1.70–15.24 Avg vol 30d6.4M Short int27.5M · 29.2% float · 3.3d Short vol60% Last earningsAug 14, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 14

Up next

Next earnings call
Feb 27, 2028 Est · unconfirmed · in 80 wks
FQ2-27 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +83%
above
Price vs 50-day avg +40%
above
RSI (14) 66
neutral
MACD trend Positive
52-week position 98%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +57%
trailing
6-month return +73%
trailing
YTD return +54%
this year
Relative strength +59%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $11 › 200d $8 — 50d above 200d
Institutional flow Accumulating
+7% holders QoQ · +73 funds added
Insider flow Distributing
Net -$906.2K over 90 days · 100% sells
Short interest Rising
29.23% of float · ▲ +16.4% MoM · 3.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
202 holders — near 3-yr high, broad support
Squeeze score 74
high risk · 0–100
Fundamentals
Weak
EPS growth −10%
Y/Y
Free cash flow $-282.6M
Balance sheet $125.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 217%
annualized · 1-yr
Max drawdown −84%
past year
ATR 10.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+83% Bullish
Price vs 50-day avg
+40% Bullish
RSI (14)
66 Neutral
MACD trend
Positive Bullish
52-week position
98% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $11 › 200d $8 — 50d above 200d
Institutional flow Accumulating
+7% holders QoQ · +73 funds added
Insider flow Distributing
Net -$906.2K over 90 days · 100% sells
Short interest Rising
29.23% of float · ▲ +16.4% MoM · 3.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
202 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $15 · 98% Range high $15
vs 200-day avg +83% vs 50-day avg +40%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
REPL
Replimune Group, Inc.
this stock
$1.41B +54.0% — — 29.2%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
202
% held
109.8%
Net QoQ
+15.1M sh
Top holder
BAKER BROS. ADVISORS LP
Held Float
View
Held by Funds
Fund positions
164
View
Short & Settlement
Short Interest Rising
Shares short
27.5M
Days to cover
3.3d
Change
+3.9M sh
View
Short Volume
Short vol %
60%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
3.2K
Value
$35.9K
As of
Jul 9, 2026
View
Off-Exchange
Off-exchange %
36.9%
Week of
Jul 6, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$906.2K
Buyers / Sellers
0 / 4
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-313.9M
EPS diluted
$-3.38
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 14, 2026
This year
16
View
Proposed Sales
Value
$142.5K
Shares
18.5K
Filed
Apr 2, 2026
View
Earnings & Events
Earnings Calls
Last call
Aug 14, 2026
View

Performance

5D 20D 120D MTD YTD
REPL +24.1% +57.3% +73.3% +33.7% +54.0%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY +23.7% +52.8% +59.5% +29.7% +40.2%
Key facts CIK 1737953 CUSIP 76029N106 13F (30d) 198 filings 192 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)